S. 5571, Biologic Drug Price Protection. Quorum's AI analysis reads it as a net cost — and names who bears it.
S. 5571 · Net cost
What it does
This bill delays when biologic drugs become eligible for Medicare price negotiations if a cheaper biosimilar (generic biologic) is expected to enter the market soon. Instead of negotiating prices immediately, the government waits up to 2 years after a biosimilar manufacturer publicly signals it is developing a competing product. If no biosimilar actually launches within 2 years, the original drug enters price negotiations and the biosimilar maker must pay rebates for the delay.
The analysis names biologic drug manufacturers (reference product makers) — and 1 more group — among the beneficiaries.
The cost
The 2-year delay is automatic upon biosimilar manufacturer disclosure—no government approval required—shifting control of negotiation timing to private companies.
The analysis put a high warning level on this bill. Transparency scores 25%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Marsha Blackburn. Cosponsored by Adam Schiff, James Lankford and Ted Budd.
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.